Skip to main content
. Author manuscript; available in PMC: 2023 May 1.
Published in final edited form as: J Control Release. 2022 Mar 14;345:306–313. doi: 10.1016/j.jconrel.2022.03.021

Fig. 4. In vivo anti-cancer activity of DAL4-LNP encapsulating single or multiple cytokine mRNAs.

Fig. 4.

(A) B16F10 tumor size after treatment of single cytokine mRNA in DAL4-LNP (n = 6). (B) Overall survival of B16F10 tumor-bearing mice. (C) B16F10 tumor size after treatment with DAL4-LNP encapsulating two or three cytokine mRNAs (n = 5–7). (D) Overall survival of B16F10 tumor-bearing mice. Data in (A) and (C) are presented as the mean ± S.E.M. Statistical significance in (A) and (C) was analyzed using two-way ANOVA with repeated measurements. Statistical significance in (B), (D) were analyzed using the log-rank (Mantel-Cox) test. *P < 0.05; **P < 0.01; ***P < 0.001.